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Abstract 
Purpose: To analyse and compare the clinical effects and safety of capecitabine and 
tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma. 
Methods: Eighty-four metastatic breast cancer elderly patients for whom first or second-line treatment 
had failed, were selected from among those admitted to the oncology ward of Binjiang People’s 
Hospital, China between January 2014 and June 2015. They were randomly divided into S-1 group (n = 
41) and capecitabine group (n = 41) and received varying doses of those drugs according to body 
surface area. Clinical effects, progression-free survival, and incidence of adverse reactions were 
compared for the two groups following treatment. 
Results: Disease control rate (CR) in S-1 group was 55.6 %, much higher than 35.1 % observed for 
capecitabine group (p < 0.05). The disease control rate for the S-1 group was 93.7 %, also much higher 
than the 70.6 % found in capecitabine group. Survival analysis showed that the median survival times of 
the two groups did not differ significantly (p > 0.05). Furthermore, some adverse reactions such as 
myelosuppression and lack of strength, did not differ significantly between the two groups (p > 0.05), 
whereas others, including leukopenia, nausea and vomiting and hand-foot syndrome were more serious 
and frequent in capecitabine group than in S-1 group (p < 0.05). 
Conclusion: Monotherapy with S-1 is more effective than that with capecitabine. Adverse reactions are 
minimal for both drugs.  
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Since the 1980s, breast cancer has had the 
highest incidence and the sixth-highest mortality 
rate of all malignant tumours in women. In many 
cases, these cancers have already progressed to 
a late stage, some with distant metastases, by 
the time of initial diagnosis [1,2]. Surgery and 
chemotherapy are the major treatment methods 
for breast cancer. To extend survival as much as 
possible, chemotherapy without surgical 
treatment is more appropriate for late-stage 
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breast cancer [3,4]. The most preferred 
chemotherapeutic drugs are anthracyclines and 
taxanes, but their toxicity and side effects can 
severely reduce treatment effectiveness 
andquality of life for elderly patients most such 
patients are intolerant of  combined 
chemotherapy. Many patients with advanced 
breast cancer have already experienced 
treatment failure using the drugs mentioned 
above. Currently, effective, safe and easy-to-
administer therapeutic regimens that can be 
maintained over the long term are lacking in 
clinics. 
 
Drugs related to 5-fluorouracil (5-FU) are 
effective in the treatment of breast cancer. Oral 
administration of capecitabine is recommended 
as a standard salvage treatment although 
adverse reactions such as hand-foot syndrome 
and gastrointestinal side effects restrict its clinical 
application [5,6]. Some studies [7,8] have 
demonstrated  significant effects achieved after a 
single treatment with S-1, with minimal adverse 
reactions. However most of the research data 
are from Japan, and few studies have been 
performed in China. This study sought to 
compare the curative effects and safety of S-1 
and capecitabine in the treatment of patients with 






Eighty-two elderly patients with advanced breast 
cancer admitted to Binzhou People’s Hospital, 
China, between January 2014 and June 2015, 
were selected.  All cases were confirmed as 
advanced breast cancer, with biopsy-proven 
invasive ductal carcinomas and distant 
metastases observed by Computed Tomography 
(CT) and Magnetic Resonance Imaging (MRI). 
The subjects were all females aged from 63 to 81 
years (median 51 years). All patients were 
observed to have tumour progression after one 
or two regimens of chemotherapy. Patients were 
included if they had measurable lesions 
according to the response evaluation criteria in 
solid tumours (RECIST) (version 1.1) [9], and 
were predicted to have at least a further 6months 
of survival, with good bone marrow, hepatic, and 
renal function. Those with rapid disease 
progression, contraindications to chemotherapy, 
organ risks, liver and kidney function deficiency, 
or uncontrolled cerebral metastasis were 
excluded. The study was approved by the 
Medical Ethics Committee of Binzhou People’s 
Hospital (approval no. BPH20140104ZDX), and 
the experiment followed the guidelines of the 
Declaration of Helsinki [10]. 
Therapeutic regimen 
 
The enrolled patients were separated into an S-1 
group and a capecitabine group using a random 
number table, 41 patients were in each group. 
Drug doses were set according to the body 
surface area (BSA) of each patient:  80 mg/day 
for BSA ≤ 1.25 m2, 100 mg/day for   BSA > 1.25 
m2 but < 1.5 m2, and 120 mg/day for BSA ≥ 
1.5m2. Patients in the S-1 group received oral S-
1 (Shandong New Age Pharmaceutical Co., Ltd., 
China; State Food and Drug Administration 
(SFDA) approval number: H20080803) twice 
daily after breakfast and supper for 28 days, and 
then stopped taking the drug for 14 days; every 6 
weeks was regarded as one cycle. Patients in 
the capecitabine group received oral 
capecitabine within 30 min after breakfast and 
supper for 14 days, and then stopped taking the 
drug for 7 days; every 3 weeks was regarded as 
one cycle. Clinical effect was evaluated every 6 
weeks. When the effect was evaluated as 
complete remission (CR), partial remission (PR), 
or stable disease (SD), treatment was continued 
until either tumours developed or intolerable 
adverse reactions appeared.  
 
Observed features and criteria for indexing 
therapeutic effect 
 
The therapeutic effect was evaluated according 
to RECIST 1.0. In CR all lesions disappeared 
and did not recur for 4 weeks. Reduction of 
lesion areas by more than 30 % and the 
appearance of no new lesions for 4 weeks was 
considered PR. An increase in lesion area or the 
appearance of new lesions was considered 
progressive disease (PD). All patients were re-
examined after two courses of treatment. Lesions 
were measured before and after treatment and 
were compared to evaluate clinical effects. The 
overall response rate (ORR) was the sum of 
percentages of patients with CR and PR; the 
disease control rate (DCR) was the sum of 
percentages of patients with CR, PR and SD. All 
patients were followed up successfully by 
telephone and/or by outpatient services. Survival 
time (in months) were recorded during follow-up 




SPSS software (ver. 12.0; SPSS Inc., USA) was 
used for statistical analysis. Categorical data 
were compared between groups using Chi-
square tests. Overall survival time was analysed 
using Kaplan-Meier plots and compared using 
log-rank tests. Differences were considered 
statistically significant if p < 0.05. 
 





Baseline characteristics and treatment 
conditions 
 
Of the 82 patients enrolled, 62 (75.6 %) had 
undergone first-line chemotherapy and 20 (24.4 
%) had received second-line chemotherapy. No 
significant difference was found in general 
characteristics or previous treatment conditions 




In S-1 group, the median number of 
chemotherapy cycles was 3.5 (1 - 11 cycles); 
after treatment, there were no cases of CR, 13 
cases of PR, 14 cases of SD, and 14 cases of 
PD. In the capecitabine group, the median 
number of chemotherapy cycles was 4 (1 - 17 
cycles); after treatment, there were no cases of 
CR, 8 cases of PR, 11 cases of SD, and 22 
cases of PD.  
 
The ORR of the S-1 and capecitabine groups 
was 31.7 % (13/41) and 19.5 % (8/41), 
respectively (X2 = 3.963, p < 0.05). The DCR of 
the two groups was 65.9 % (27/41) and 46.3 % 
(19/41), respectively (X2 = 6.440, p < 0.05). 




Long-term survival rate 
 
Kaplan-Meier analysis indicated that the median 
progression-free survival (PFS) for the S-1 group 
and the capecitabine group was 5.5 and 4.5 
months, respectively (95 % confidence intervals: 
4.7 - 6.3 and 2.4 - 5.6 months); this difference 
was not statistically significant (X2 = 0.219, p > 
0.05; Figure 1). 
 
 
Figure 1: The progression-free survival (PFS) curves 




Some adverse reactions, such as 
myelosuppression and lack of strength, did not 
differ significantly between the two groups (p > 
0.05). Leucopenia, nausea and vomiting, and 
hand-foot syndrome in the capecitabine group 
were more serious and more frequent than in the 
S-1 group (p < 0.05; Table 2). 
 
Table 1: Baseline characteristics of the two groups 
 




Median age (years) 69.4±5.6 70.1±5.3   






Luminal B 16(39.0%) 18(43.9%) 
HER2 overexpression 9(22.0%) 10(24.4%) 
Triple negative 11(26.8%) 6(14.6%) 
Menstrual state Non-menopausal 13(31.7%) 17(41.5%) 1.078 >0.05 Post-menopausal 28(68.3%) 24(58.5%) 
Number of metastatic lesions 
(n) 
1 12(29.3%) 9(22.0%)  
1.372 
 
>0.05 2-3 21(51.2%) 24(58.5%) ≥4 8(19.5%) 8(19.5%) 
History of pulmonary 
metastasis 
With 22(53.7%) 24(58.5%) 0.158 >0.05 Without 19(46.3%) 17(41.5%) 
History of liver metastasis With 25(61.0%) 20(48.8%) 1.267 >0.05 Without 16(39.0%) 21(51.2%) 
Chemotherapy cycle number 
(n) 
1 27(65.9%) 31(75.6%) 1.178 >0.05 2 14(34.1%) 10(24.4%) 
Salvage chemotherapy with 
anthracyclines 
With 23(56.1%) 19(46.3%) 0.016 >0.05 Without 18(43.9%) 22(53.7%) 
Salvage chemotherapy with 
taxanes 
With 34(82.9%) 30(73.2%) 2.217 >0.05 Without 7(17.1%) 11(26.8%) 
Salvage chemotherapy with 
platinum 
With 20(48.8%) 22(53.7%) 1.305 >0.05 Without 21(51.2%) 19(46.3%) 
Note: A group: S-1 group; B group: Capecitabine group; HER2: human epidermal growth factor receptor 2 
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Table 2: Incidence of adverse reactions between the two groups (N, %) 
 
Group A group B group X2 p 
Myelosuppression 14(34.1%) 13(31.7%) 0.027 >0.05 
Lack of strength 29(70.7%) 32(78.4%) 0.051 >0.05 
Leukopenia 10(24.4%) 28(68.3%) 7.648 <0.05 
Nausea and vomiting 14(34.1%) 39(95.1%) 4.847 <0.05 
Hand-foot syndrome 9(22.0%) 30(73.2%) 5.906 <0.05 




Breast cancer usually becomes metastatic at an 
advanced stage, at which point it is difficult to 
treat. Surgical treatment that is suitable at an 
early stage is not applicable in late-stage 
disease. The wide distribution of lesions and their 
significant invasion of surrounding tissues mean 
that surgery cannot effectively remove them. 
Therefore, palliative treatment is frequently used 
for patients with advanced breast cancer, with 
the intention of extending survival time [11]. 
Many guidelines recommend single-agent 
sequential chemotherapy as the first choice for 
patients with metastatic breast cancer. Although 
combination chemotherapy may result in higher 
RRs and longer PFS, it does not confer a 
survival advantage, and the incidence of toxicity 
and side effects is significantly increased [12]. 
Single-agent sequential chemotherapy is thus 
more beneficial in terms of quality of life. A 
human pharmacodynamics study [13] suggested 
that capecitabine, which can be absorbed well, 
generated a significantly higher concentration of 
fluorouracil in tumour tissues than in adjacent 
normal tissues. A study by Ershler WB [14] 
demonstrated that capecitabine could exert an 
objective effect on advanced breast cancer and 
was, moreover, effective and safe. While toxic 
reactions to capecitabine were controllable in the 
treatment of weakened patients with advanced 
breast cancer, there was a high risk of renal 
function impairment in the elderly [14]. Another 
study [15] enrolled 236 patients with advanced 
breast cancer previously treated with 
anthracyclines and taxanes, and treated them 
with capecitabine; the RR and median PFS were 
23.3 % and 4.7 months, respectively, and 
remission was sustained in patients with 
oestrogen receptor-positive cancers and single 
metastatic lesions . In the present study, the RR 
of the capecitabine group was 19.5 %, and the 
median PFS was 4.5 months, suggesting good 
tolerance that was consistent with previous 
research results. S-1, a fluorouracil-based 
anticancer drug composed of tegafur, gimeracil, 
and oteracil potassium, can effectively inhibit 
dihydropyrimidine dehydrogenase and extend 
the duration of effective 5-FU concentrations in 
tumour tissues and surrounding blood. Oteracil 
potassium can selectively inhibit the activity of 5-
FU metabolic enzymes, reduce the 
phosphorylation of 5-FU, and lessen its toxic 
effects in the digestive tract. Compared to 
capecitabine, S-1 can maintain higher plasma 
drug concentrations, improve anticancer activity, 
significantly reduce toxicity, and be administrated 
conveniently. A Japanese phase II clinical study 
[16] verified the efficacy and safety of S-1 in the 
treatment of breast cancer. In that study, 108 
patients with advanced breast cancer resistant to 
taxol were treated with S-1; the RR and median 
survival time was 41.7 % and 872 d, respectively; 
grade III - IV toxic reactions included leukopenia 
(9.1 %), fatigue (2.7 %) and poor appetite (3.6 
%), yielding S-1 a high safety rating.  
 
Yuan et al [17] carried out a phase II clinical 
study on 33 patients for whom previous 
treatment with taxanes and anthracyclines and 
had failed. As second-line mono-chemotherapy, 
the median PFS and RR with S-1 were 3.3 
months and 33.3 %, respectively. The present 
study found a CR rate for S-1 group of 31.7 %, 
which was much higher than the 19.5 % seen in 
the capecitabine group; the overall DCR of the S-
1 group was 65.9%, much higher than the 46.3 
% seen with capecitabine. Some adverse 
reactions, such as leukopenia, nausea and 
vomiting, and hand-foot syndrome were more 
serious in capecitabine group than in S-1 group 
(p < 0.05). 
 
Limitation of the study 
 
The number of cases enrolled in the study was 
small, and the observation time was not long. 
Hence, longer studies with a larger sample size 
are required to further investigate the clinical 




The findings of this study indicate that S-1 has a 
higher efficacy than capecitabine, and also that it 
induced minimal toxicity and side reactions in 
advanced breast cancer patients for whom 
previous treatment with anthracyclines and 
taxanes failed. Therefore, S-1 seems a better 
choice than capecitabine in the clinical treatment 
of advanced breast cancer. 
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